Biomerica Announces Reverse Stock Split
IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) ("Biomerica"), a global provider of advanced medical products, today announced that it will implement a 1-for-8 ...
Model output · Signal date 2026-11-06
Biomerica Inc (BMRA) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
18.0%
Spearman, 357 dates
Market Cap
$7M
small-cap · #13 of 17 peers
Summary
Biomerica Inc (BMRA) stock forecast summary
Our AI scores Biomerica Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Biomerica Inc is a small-cap company with a market capitalization of $7M. It ranks number 13 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its ROE of -141.9% is the lowest of the 10 peers that report one. Its Gross Margin of 12.1% is the lowest of the 9 peers that report one.
For BMRA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -12.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BMRA included.
Price
BMRA price chart and AI forecast
Cross-section · 2026-11-06
How BMRA ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-08-31
Biomerica Inc (BMRA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | BMRA | Rank |
|---|---|---|
| Market Cap | $7M | 13/17 |
| P/B Ratio | 2.03x | 8/12 |
| EPS | $-0.81 | – |
| Book Value/Share | $0.79 | – |
Profitability & Margins
| Metric | BMRA | Rank |
|---|---|---|
| ROE | -141.9% | 10/10 |
| ROA | -64.2% | 10/12 |
| ROIC | -95.8% | 12/12 |
| Gross Margin | 12.1% | 9/9 |
| Operating Margin | -112.7% | 9/14 |
| Net Margin | -116.4% | 8/11 |
| EBT Margin | -86.3% | 9/14 |
| Tax Rate | -0.6% | – |
Financial Health
| Metric | BMRA | Rank |
|---|---|---|
| Current Ratio | 1.91x | 11/16 |
| Quick Ratio | 1.33x | 7/10 |
| D/E Ratio | 1.21x | 3/12 |
| Financial Leverage | 2.21x | 3/12 |
| Interest Coverage | -7344.2x | 15/15 |
| Working Capital | $3M | 13/16 |
Cash Flow
| Metric | BMRA | Rank |
|---|---|---|
| Operating Cash Flow | -$3M | 5/16 |
Operational Efficiency
| Metric | BMRA | Rank |
|---|---|---|
| Inventory Turnover | 2.6x | 8/10 |
| Days Inventory | 139 days | 3/10 |
| Payables Period | 127 days | 3/10 |
Income Statement
| Metric | BMRA | Rank |
|---|---|---|
| Operating Income | -$5M | 4/15 |
| Net Income | -$5M | 4/12 |
| R&D Expense | $790K | 15/16 |
| SG&A Expense | $5M | 12/12 |
| Cost of Goods Sold | $4M | 8/10 |
Dividend & Shareholder Information
| Metric | BMRA | Rank |
|---|---|---|
| Shares Outstanding | 5M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $5M | 67.1% of assets |
| Cash & Short-term Investments | $3M | 33.8% of assets |
| Accounts Receivable | $900K | 11.2% of assets |
| Inventory | $2M | 20.2% of assets |
| Total Liabilities | $4M | 54.8% of assets |
| Short-term Debt | $1M | 16.6% of assets |
Quarterly Financial Reports
BMRA quarterly financials and insider trading
Industry Peers · In Vitro & In Vivo Diagnostic Substances
Biomerica Inc (BMRA) industry peers
Companies classified under the same SEC industry code as Biomerica Inc (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BMRA Biomerica Inc | $7M | |
| IDXX Idexx Laboratories Inc /De | $53.26B | |
| LNTH Lantheus Holdings, Inc. | $6.57B | |
| NEOG Neogen Corp | $2.57B | |
| CLDX Celldex Therapeutics, Inc. | $2.35B | |
| NTLA Intellia Therapeutics, Inc. | $1.59B | |
| QDEL Quidelortho Corp | $734M | |
| ACHV Achieve Life Sciences, Inc. | $692M | |
| MYGN Myriad Genetics Inc | $566M | |
| TKNO Alpha Teknova, Inc. | $482M | |
| ICCC Immucell Corp /De/ | $90M | |
| IMDX Insight Molecular Diagnostics Inc. | $81M | |
| AWHL Aspira Women's Health Inc. | $9M | |
| CDIO Cardio Diagnostics Holdings, Inc. | $5M | |
| TRIB Trinity Biotech Plc | $5M | |
| QCLS Q/C Technologies, Inc. | $3M | |
| VNRX Volitionrx Ltd | $3M |
Where BMRA sits on the market map
Life Sciences · In Vitro & In Vivo Diagnostic Substances
News
Biomerica Inc (BMRA) stock news
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a developer and manufacturer of diagnostic test systems and CDMO services provider, today announced it has entered into ...
Biomerica, Inc. (BMRA) Announces Dubai Government Grants Insurance Reimbursement for EZ Detect Colorectal Disease Screening Test
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that the Dubai government has officially approved insurance reimbursement for the EZ Detect colorectal disease at-home screening test, ...
FAQ
Biomerica Inc (BMRA) stock forecast FAQ
What is the Biomerica Inc (BMRA) stock forecast?
Our AI scores Biomerica Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Biomerica Inc stock predictions?
For BMRA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -12.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Biomerica Inc forecasts updated?
Biomerica Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Biomerica Inc's industry peers?
17 issuers in our coverage, BMRA included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.